Page 79 - Glucose Monitoring Devices

References 77

[88] Zhou H, et al. A computer simulation model of diabetes progression, quality of life, and
cost. Diabetes Care 2005;28(12):2856e63.
[89] Willis M, Johansen P, Nilsson A, Asseburg C. Validation of the economic and health
outcomes model of type 2 diabetes mellitus (ECHO-T2DM). PharmacoEconomics
2017;35(3):375e96.
[90] Palmer AJ, et al. The core diabetes model: projecting long-term clinical outcomes, costs
and cost effectiveness of interventions in diabetes mellitus (types 1 and 2) to support
clinical and reimbursement decision-making. Current Medical Research and Opinion
2004;20(Suppl. 1):S5e26.
[91] McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS
CORE diabetes model. Value in Health 2014;17(6):714e24.
[92] Fortwaengler K, Campos-Na ´n ˜ez E, Parkin CG, Breton MD. The financial impact of
inaccurate blood glucose monitoring systems. Journal of Diabetes Science and Technol-
ogy 2018;12(2):318e24.
[93] Fanshel S, Bush JW. A health-status index and its applications to health-services
outcomes. Operations Research 1970;18(6):967e1235.
[94] Rodbard D. State of type 1 diabetes care in the United States in 2016e2018 from T1d
exchange registry data. Diabetes Technology and Therapeutics 2019;21(2):62e5.
[95] Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of
microvascular complications in type 1 diabetes. Diabetes Care 2006;29(7):1486e90.
[96] Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as
assessed by Continuous Glucose Monitoring (CGM) and diabetic retinopathy in type 1
and type 2 diabetes. Acta Diabetologica 2013;50(3):437e42.